Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | HTR1D | P28221 | 3/20 | 0.47 |
| ▸ | HEXA | P06865 | 1/20 | 0.42 |
| ▸ | HEXB | P07686 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24746655 | 0.82 | HTR2C (0.58) | HTR2CHTR2AHTR1DHEXAHEXB | |
| SCHEMBL24746489 | 0.81 | HTR2C (0.59) | HTR2CHTR2AHTR1DHEXAHEXB | |
| SCHEMBL23956119 | 0.81 | HTR2C (0.57) | HTR2CHTR2AHTR1DHEXAHEXB | |
| SCHEMBL23927911 | 0.78 | HTR2C (0.54) | HTR2CHTR2AHTR1DHEXAHEXB | |
| SCHEMBL24130695 | 0.78 | CYP19A1 (0.39) | HTR2CHTR2AHTR6 | |
| SCHEMBL337413 | 0.74 | HTR2C (0.68) | HTR2CHTR2AHTR1DHTR6 | |
| SCHEMBL4060777 | 0.73 | HTR2C (1.00) | HTR2CHTR2AHTR1DHTR6 | |
| SCHEMBL23927820 | 0.72 | HTR2A (0.50) | HTR2CHTR2AHTR1DHTR6 | |
| SCHEMBL2866149 | 0.72 | KDM4E (0.41) | POLB | |
| SCHEMBL30847966 | 0.71 | PRKCI (0.39) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| EP-1648444-B1 | INDOL-7 SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | ESTEVE LABOR DR (ES) | 2009-06-03 | — | — | EP | disclosed |
| EP-1648468-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2008-09-24 | — | — | EP | disclosed |
| US-7414070-B2 | Indol-7-YL sulfonamide derivatives, their preparation and their use in pharmaceutical compositions | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-19 | — | — | US | disclosed |
| US-20070185207-A1 | Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR ESTEVE S.A (ES) | 2007-08-09 | — | — | US | disclosed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| CN-1832739-A | Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | ESTEVE LABOR DR (ES) | 2006-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | HTR6, NPY5R, NPY2R | HTR2C 23/4885HTR2A 18/4885HTR1D 50/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | HTR2C 23/4885HTR2A 18/4885HTR1D 50/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | HTR2C 32/4885HTR2A 19/4885HTR1D 69/4885 |
| US-20070185207-A1 | Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | HTR6, HTR7, TPH1 | HTR2C 7/4885HTR2A 14/4885HTR1D 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.